Our most recent study indicated that inpatients using ACE inhibitors or angiotensin II receptor blockers are at significantly lower risk of 28-day all-cause death compared with nonusers in patients with hypertension hospitalized with COVID-19.21 Autopsy analysis of hearts from COVID-19 patients suggested a potential involvement of systematic inflammation in heart injury.22 However, there are, so far, no data directly demonstrating the presence of SARS-CoV-2 within myocardial tissue or the direct influence of renin-angiotensin-aldosterone system inhibitors on heart injury in COVID-19 patients. This evidence concerns the gene ACE and COVID-19.